Drug:
Reaction: NO ADVERSE EVENT
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26940129 |
US |
1 | |
Product delivery mechanism issue, Device information output issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 2 | 26940208 |
US |
||
Device issue, No adverse event, |
||||
RISPERIDONE, |
||||
| 3 | 26940406 |
US |
81 | 1 |
Drug delivery system malfunction, No adverse event, Product dose omission issue, |
||||
TOCILIZUMAB, |
||||
| 4 | 26940433 |
US |
1 | |
Product adhesion issue, No adverse event, |
||||
SCOPOLAMINE TRANSDERMAL SYSTEM, SCOPOLAMINE TRANSDERMAL SYSTEM, |
||||
| 5 | 26940435 |
US |
2 | |
Product quality issue, Product adhesion issue, No adverse event, |
||||
SCOPOLAMINE TRANSDERMAL SYSTEM, SCOPOLAMINE TRANSDERMAL SYSTEM, |
||||
| 6 | 26940436 |
US |
2 | |
Product adhesion issue, No adverse event, |
||||
SCOPOLAMINE TRANSDERMAL SYSTEM, SCOPOLAMINE TRANSDERMAL SYSTEM, |
||||
| 7 | 26940548 |
US |
||
Product storage issue, No adverse event, |
||||
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, |
||||
| 8 | 26940751 |
US |
2 | |
Incorrect dose administered by device, Device failure, Device malfunction, Device mechanical issue, No adverse event, |
||||
LIRAGLUTIDE, |
||||
| 9 | 26940764 |
US |
41 | 2 |
Incorrect dose administered by device, Device difficult to use, Device mechanical issue, No adverse event, |
||||
LIRAGLUTIDE, LIRAGLUTIDE, |
||||
| 10 | 26941239 |
US |
||
Underdose, Device loosening, No adverse event, |
||||
OCRELIZUMAB, |
||||
| 11 | 26941263 |
US |
1 | |
Product delivery mechanism issue, Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 12 | 26941393 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 13 | 26941742 |
US |
||
Manufacturing product shipping issue, Product dose omission issue, No adverse event, Product packaging issue, Product physical issue, Product container seal issue, |
||||
SITAGLIPTIN, |
||||
| 14 | 26941745 |
US |
||
No adverse event, Device malfunction, No adverse event, Device malfunction, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 15 | 26941970 |
US |
5 | |
Poor quality product administered, No adverse event, |
||||
FAMOTIDINE, FAMOTIDINE, FAMOTIDINE, ERGOCALCIFEROL, |
||||
| 16 | 26942220 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 17 | 26942328 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 18 | 26942478 |
US |
1 | |
Product quality issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 19 | 26942712 |
US |
||
Product dose omission issue, Product use issue, No adverse event, |
||||
SITAGLIPTIN PHOSPHATE, |
||||
| 20 | 26942901 |
US |
||
Product use issue, No adverse event, |
||||
AMLODIPINE BESYLATE, |
||||
| 21 | 26942955 |
US |
||
Product storage issue, No adverse event, |
||||
OCRELIZUMAB, |
||||
| 22 | 26942992 |
US |
86 | |
Recalled product administered, No adverse event, |
||||
LIRAGLUTIDE, EMPAGLIFLOZIN, |
||||
| 23 | 26942997 |
US |
47 | 1 |
Intentional dose omission, No adverse event, |
||||
AVAPRITINIB, |
||||
| 24 | 26943035 |
US |
2 | |
Product dose omission issue, Device breakage, No adverse event, Device connection issue, Product preparation error, |
||||
SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, |
||||
| 25 | 26943127 |
US |
2 | |
Pregnancy, No adverse event, |
||||
VEDOLIZUMAB, |
||||
| 26 | 26943169 |
US |
||
No adverse event, Product temperature excursion issue, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 27 | 26943343 |
71 | 2 | |
No adverse event, |
||||
NALTREXONE, |
||||
| 28 | 26943577 |
US |
79 | |
Drug dose omission by device, Wrong technique in product usage process performed in error, Product use issue, No adverse event, |
||||
ALBUTEROL SULFATE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, AMLODIPINE, LISINOPRIL, |
||||
| 29 | 26943668 |
US |
43 | |
Drug dose omission by device, Wrong technique in product usage process performed in error, Prescription drug used without a prescription, Incorrect dose administered by device, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 30 | 26943985 |
US |
89 | 2 |
Wrong technique in product usage process, Device difficult to use, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 31 | 26944628 |
US |
1 | |
Product dose omission issue, No adverse event, |
||||
| 32 | 26944878 |
US |
||
Product storage error, No adverse event, |
||||
PERTUZUMAB, |
||||
| 33 | 26945576 |
US |
2 | |
Incorrect dose administered, Wrong technique in product usage process, No adverse event, |
||||
OMALIZUMAB, |
||||
| 34 | 26945596 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, |
||||
| 35 | 26945618 |
US |
2 | |
Underdose, Device defective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, EPINEPHRINE, |
||||
| 36 | 26945635 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, CLONAZEPAM, |
||||
| 37 | 26945640 |
US |
2 | |
Product packaging issue, Product dose omission issue, Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 38 | 26945662 |
US |
||
Product storage error, No adverse event, |
||||
OMALIZUMAB, |
||||
| 39 | 26945664 |
US |
2 | |
Product storage error, No adverse event, |
||||
OMALIZUMAB, |
||||
| 40 | 26945667 |
US |
||
Product storage error, No adverse event, |
||||
OMALIZUMAB, |
||||
| 41 | 26945710 |
US |
37 | 2 |
Incorrect dose administered, Needle issue, Liquid product physical issue, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 42 | 26945746 |
US |
65 | 2 |
Medication error, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 43 | 26947099 |
US |
||
Product dose omission issue, No adverse event, |
||||
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE, |
||||
| 44 | 26947254 |
US |
||
Product dose omission issue, No adverse event, |
||||
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE, |
||||
| 45 | 26934096 |
US |
38 | 2 |
Off label use, No adverse event, |
||||
BEVACIZUMAB, |
||||
| 46 | 26934421 |
US |
63 | 2 |
Product dose omission issue, Device malfunction, No adverse event, |
||||
TOCILIZUMAB, HYDROXYCHLOROQUINE SULFATE, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, FOLIC ACID, MELOXICAM, ESOMEPRAZOLE MAGNESIUM, MONTELUKAST SODIUM, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 47 | 26934763 |
US |
2 | |
Pregnancy, Device issue, No adverse event, |
||||
| 48 | 26934901 |
CA |
44 | 2 |
Type 2 diabetes mellitus, Folliculitis, Peripheral venous disease, Obesity, Diarrhoea, Depression, Osteoarthritis, Exposure during pregnancy, Abdominal pain upper, Live birth, Impaired healing, Off label use, Sciatica, Lip dry, Glossodynia, Weight increased, Fibromyalgia, Joint swelling, Gastrooesophageal reflux disease, Discomfort, Dizziness, Alopecia, Nasopharyngitis, Paraesthesia, Night sweats, Vomiting, Lower respiratory tract infection, C-reactive protein increased, Delirium, Asthenia, Decreased appetite, Peripheral swelling, Epilepsy, Synovitis, Pregnancy, Urticaria, Intentional product use issue, Blepharospasm, Hypocholesterolaemia, Drug ineffective, Nail disorder, Product quality issue, Musculoskeletal pain, Pericarditis, Muscle injury, Bursitis, Infusion related reaction, Facet joint syndrome, Hepatic enzyme increased, Stomatitis, Injury, Dry mouth, Contraindicated product administered, Systemic lupus erythematosus, No adverse event, Condition aggravated, Drug hypersensitivity, Pemphigus, Maternal exposure timing unspecified, Memory impairment, X-ray abnormal, Blood cholesterol increased, Drug intolerance, Hand deformity, Arthralgia, Wheezing, Adverse drug reaction, Breast cancer stage III, Confusional state, Hypoaesthesia, Rash, Blister, Prescribed overdose, Joint range of motion decreased, Taste disorder, Anti-cyclic citrullinated peptide antibody positive, Adverse event, General physical health deterioration, Product use in unapproved indication, Wound infection, Psoriatic arthropathy, Abdominal discomfort, Abdominal pain, Sinusitis, Irritable bowel syndrome, Liver injury, Duodenal ulcer perforation, Helicobacter infection, Hypertension, Mobility decreased, Arthropathy, Inflammation, Migraine, Pain, Muscle spasms, Swelling, Wound, Lung disorder, Normal newborn, Hypercholesterolaemia, Headache, Fatigue, Maternal exposure during pregnancy, Malaise, Rheumatoid arthritis, |
||||
METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, DICLOFENAC, DICLOFENAC SODIUM, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, VEDOLIZUMAB, CHLORHEXIDINE GLUCONATE, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, ALENDRONATE SODIUM, LAMOTRIGINE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, DESOXIMETASONE, TRAMADOL HYDROCHLORIDE, DICLOFENAC SODIUM, DICLOFENAC SODIUM, DICLOFENAC SODIUM, SECUKINUMAB, CERTOLIZUMAB PEGOL, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, ALENDRONATE SODIUM, ALENDRONATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 49 | 26934906 |
US |
91 | 2 |
No adverse event, Syringe issue, |
||||
AVACINCAPTAD PEGOL, AVACINCAPTAD PEGOL, AVACINCAPTAD PEGOL, AVACINCAPTAD PEGOL, AVACINCAPTAD PEGOL, AVACINCAPTAD PEGOL, |
||||
| 50 | 26935230 |
US |
1 | |
Drug dose omission by device, Device defective, Device leakage, Device failure, No adverse event, |
||||
LIRAGLUTIDE, |
||||
| 51 | 26935278 |
US |
54 | |
Off label use, No adverse event, |
||||
ROPEGINTERFERON ALFA-2B, |
||||
| 52 | 26935508 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
AVAPRITINIB, |
||||
| 53 | 26935558 |
US |
2 | |
Incorrect dose administered by device, Device failure, Device mechanical issue, No adverse event, |
||||
LIRAGLUTIDE, LIRAGLUTIDE, |
||||
| 54 | 26935720 |
2 | ||
Product dose omission issue, Device issue, No adverse event, |
||||
AZELASTINE, |
||||
| 55 | 26935806 |
US |
60 | 1 |
Off label use, Device malfunction, Product dose omission issue, No adverse event, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 56 | 26936046 |
JP |
||
Product contamination physical, No adverse event, |
||||
ABATACEPT, |
||||
| 57 | 26936074 |
US |
||
Recalled product administered, No adverse event, |
||||
LIRAGLUTIDE, |
||||
| 58 | 26936141 |
US |
||
Recalled product administered, No adverse event, |
||||
LIRAGLUTIDE, |
||||
| 59 | 26936195 |
US |
10 | 2 |
Product dose omission issue, Device malfunction, Device defective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 60 | 26936247 |
US |
2 | |
Off label use, No adverse event, |
||||
OCRELIZUMAB, |
||||
| 61 | 26936260 |
US |
50 | |
Recalled product administered, No adverse event, |
||||
LIRAGLUTIDE, |
||||
| 62 | 26936265 |
US |
73 | |
Drug dose omission by device, Recalled product administered, Device leakage, No adverse event, |
||||
PREDNISOLONE ACETATE, LISINOPRIL, |
||||
| 63 | 26936378 |
US |
2 | |
Product availability issue, No adverse event, |
||||
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE, LISDEXAMFETAMINE DIMESYLATE CAPSULES, |
||||
| 64 | 26936420 |
US |
22 | 1 |
Device dispensing issue, Device delivery system issue, No adverse event, |
||||
OMALIZUMAB, |
||||
| 65 | 26936483 |
US |
1 | 1 |
Expired product administered, No adverse event, |
||||
| 66 | 26936886 |
US |
2 | |
Product storage error, No adverse event, |
||||
| 67 | 26936895 |
US |
2 | |
Product dose omission issue, No adverse event, |
||||
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE, |
||||
| 68 | 26936939 |
US |
||
Drug ineffective, No adverse event, |
||||
AVAPRITINIB, |
||||
| 69 | 26936943 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
AVAPRITINIB, AVAPRITINIB, |
||||
| 70 | 26937050 |
US |
66 | |
Incorrect dose administered, Product taste abnormal, No adverse event, |
||||
POLYETHYLENE GLYCOL-3350 AND ELECTROLYTES, |
||||
| 71 | 26937367 |
AU |
85 | 2 |
Device failure, Wrong technique in device usage process, Product dose omission issue, Device safety feature issue, No adverse event, |
||||
ABATACEPT, |
||||
| 72 | 26937377 |
US |
1 | 2 |
Product storage issue, No adverse event, |
||||
| 73 | 26937432 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
OCRELIZUMAB, |
||||
| 74 | 26937443 |
US |
11 | 1 |
Device issue, Product dose omission issue, No adverse event, |
||||
ETEPLIRSEN, ETEPLIRSEN, LISINOPRIL, DEFLAZACORT, VAMOROLONE, BUDESONIDE AND FORMOTEROL FUMARATE, |
||||
| 75 | 26937444 |
US |
25 | 1 |
Intentional dose omission, No adverse event, |
||||
ETEPLIRSEN, ETEPLIRSEN, ETEPLIRSEN, ENALAPRIL MALEATE, ENALAPRIL, CARVEDILOL, DEFLAZACORT, METOPROLOL TARTRATE, SPIRONOLACTONE, SACUBITRIL AND VALSARTAN, EMPAGLIFLOZIN, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, |
||||
| 76 | 26937450 |
US |
17 | 1 |
Intentional dose omission, Product temperature excursion issue, No adverse event, |
||||
ETEPLIRSEN, ENALAPRIL MALEATE, ENALAPRIL, PREDNISOLONE SODIUM PHOSPHATE, |
||||
| 77 | 26937454 |
US |
19 | |
Intentional dose omission, No adverse event, |
||||
ETEPLIRSEN, |
||||
| 78 | 26937455 |
US |
7 | 1 |
Intentional dose omission, No adverse event, |
||||
ETEPLIRSEN, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, ERGOCALCIFEROL, |
||||
| 79 | 26937456 |
US |
15 | 1 |
Intentional dose omission, No adverse event, |
||||
ETEPLIRSEN, |
||||
| 80 | 26937460 |
US |
3 | 1 |
Product dose omission issue, Product distribution issue, No adverse event, |
||||
ETEPLIRSEN, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 81 | 26937463 |
US |
17 | 1 |
Product dose omission issue, Insurance issue, No adverse event, |
||||
ETEPLIRSEN, SPIRONOLACTONE, LISINOPRIL, |
||||
| 82 | 26937464 |
US |
1 | |
Intentional dose omission, No adverse event, |
||||
ETEPLIRSEN, VAMOROLONE, GIVINOSTAT, SACUBITRIL AND VALSARTAN, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, |
||||
| 83 | 26937465 |
US |
25 | 1 |
Poor venous access, Intentional dose omission, No adverse event, |
||||
ETEPLIRSEN, LOSARTAN POTASSIUM, LOSARTAN, VITAMIN C, ERGOCALCIFEROL, CARVEDILOL, |
||||
| 84 | 26937466 |
US |
23 | 1 |
Intentional dose omission, No adverse event, |
||||
ETEPLIRSEN, ETEPLIRSEN, ASCORBIC ACID, CARVEDILOL, LEVETIRACETAM, LISINOPRIL, |
||||
| 85 | 26937472 |
US |
6 | 1 |
Product dose omission issue, No adverse event, |
||||
ETEPLIRSEN, PREDNISONE, GABAPENTIN, |
||||
| 86 | 26937487 |
US |
10 | 1 |
Poor venous access, Product dose omission issue, No adverse event, |
||||
ETEPLIRSEN, ETEPLIRSEN, |
||||
| 87 | 26937507 |
US |
22 | 1 |
Poor venous access, Intentional dose omission, No adverse event, |
||||
ETEPLIRSEN, LISINOPRIL, SPIRONOLACTONE, FAMOTIDINE, ESCITALOPRAM, |
||||
| 88 | 26937550 |
US |
24 | 1 |
Product dose omission issue, No adverse event, |
||||
ETEPLIRSEN, ENALAPRIL MALEATE, LISINOPRIL, SULFAMETHOXAZOLE AND TRIMETHOPRIM, MUPIROCIN, MUPIROCIN CALCIUM, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, |
||||
| 89 | 26937551 |
US |
25 | 1 |
Intentional dose omission, No adverse event, |
||||
ETEPLIRSEN, ETEPLIRSEN, ETEPLIRSEN, CARVEDILOL, ENALAPRIL MALEATE, ENALAPRIL, SACUBITRIL AND VALSARTAN, EMPAGLIFLOZIN, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, |
||||
| 90 | 26937555 |
US |
9 | 1 |
Poor venous access, No adverse event, |
||||
ETEPLIRSEN, ETEPLIRSEN, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, EPINEPHRINE, ADRENALINUM, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, |
||||
| 91 | 26937557 |
US |
0 | 1 |
Product dose omission issue, No adverse event, |
||||
ETEPLIRSEN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, FAMOTIDINE, CALCIUM, LISINOPRIL, |
||||
| 92 | 26937559 |
US |
16 | 2 |
Suspected COVID-19, Exposure to SARS-CoV-2, Intentional dose omission, No adverse event, |
||||
ETEPLIRSEN, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, GABAPENTIN, LOSARTAN POTASSIUM, LOSARTAN, SERTRALINE HYDROCHLORIDE, |
||||
| 93 | 26937560 |
US |
27 | 1 |
Intentional dose omission, No adverse event, |
||||
ETEPLIRSEN, PREDNISONE, LISINOPRIL, |
||||
| 94 | 26937572 |
US |
19 | 1 |
Intentional dose omission, No adverse event, |
||||
ETEPLIRSEN, CARVEDILOL, EPLERENONE, LISINOPRIL, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 95 | 26937573 |
US |
9 | 1 |
Product communication issue, Product dose omission issue, No adverse event, |
||||
ETEPLIRSEN, |
||||
| 96 | 26937574 |
US |
6 | 1 |
Product dose omission issue, No adverse event, |
||||
ETEPLIRSEN, FERROUS SULFATE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 97 | 26937576 |
US |
18 | 1 |
Product dose omission issue, No adverse event, |
||||
ETEPLIRSEN, MELATONIN, SPIRONOLACTONE, LISINOPRIL, |
||||
| 98 | 26937577 |
US |
18 | 1 |
Poor venous access, Product dose omission issue, Device issue, No adverse event, |
||||
ETEPLIRSEN, ETEPLIRSEN, ENALAPRIL MALEATE, ENALAPRIL, PREDNISOLONE SODIUM PHOSPHATE, |
||||
| 99 | 26937578 |
US |
18 | 1 |
Physical product label issue, Product dose omission issue, No adverse event, |
||||
ETEPLIRSEN, CARVEDILOL, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, DEFLAZACORT, |
||||
| 100 | 26937596 |
US |
25 | 1 |
Device issue, Product dose omission issue, No adverse event, |
||||
ETEPLIRSEN, ETEPLIRSEN, PREDNISONE, LISINOPRIL, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30